KEY POINTS
- This nationwide Japanese prospective observational registry evaluated 96 patients with cT3N0M0 non-small cell lung cancer treated with proton beam therapy (PBT) or carbon-ion radiotherapy (CIRT) at 15 institutions between May 2016 and June 2021. Median age was 76.5 years, 41.7% were aged ≥80, and 78.1% were considered unsuitable for lobectomy. Median tumor diameter was 5.3 cm, with 77.1% having tumors larger than 5 cm and 29.2% having centrally located disease.
- Seventy patients (72.9%) received PBT and 26 (27.1%) received CIRT. Fractionation was individualized according to tumor geometry and organ-at-risk constraints, with peripheral lesions generally treated using shorter schedules and central lesions using more fractions. The most common prescriptions were 80 Gy(RBE) in 20 fractions (20%) and 72.6 Gy(RBE) in 22 fractions (17%). Only six patients received chemotherapy, including one concurrently.
- With median follow-up of 53 months, three-year overall survival was 48.1% (95% CI 38.4–60.3%). Three-year progression-free survival was 33.0% (95% CI 24.3–44.8%), while the cumulative incidence of local failure was 19.2% (95% CI 10.8–29.6%). At five years, OS, PFS, and local failure incidence were 34.5%, 23.4%, and 22.5%, respectively. These outcomes reflect a predominantly elderly, medically inoperable population rather than patients eligible for standard surgical management.
- Local and distant recurrence patterns differed. At last follow-up, 42 patients had experienced recurrence, including 12 local-only failures, two local plus regional failures, one local plus distant failure, two isolated regional failures, and 25 distant-only failures. The three-year cumulative incidence of regional failure was 4.6%, compared with 30.9% for distant failure. Of 54 deaths, 30 were attributed to lung cancer, 15 to other causes, and nine had an unknown cause.
- Reported severe treatment-related toxicity was relatively uncommon. Grade ≥3 adverse events occurred in 5/96 patients (5.2%), all grade 3, including three cases of radiation pneumonitis, one pulmonary hypertension event, and one lung infection. No grade 4–5 toxicity was reported. However, the registry systematically collected only grade ≥3 nonhematological events, limiting assessment of moderate toxicity and patient-reported morbidity.
- Interstitial lung disease remained an important adverse prognostic factor. Among 17 patients with concomitant interstitial lung disease, two (11.8%) developed grade 3 radiation pneumonitis. Both interstitial lung disease and reduced baseline vital capacity were independently associated with worse OS and PFS. Tumor diameter >5 cm, particle modality, and chemotherapy were not statistically significant survival predictors, but the small numbers prevent reliable conclusions about equivalence across subgroups.
- The registry cannot establish a clinical advantage over photon-based SBRT or conventional RT. Proton and carbon-ion treatments were pooled despite different biological dose modeling and heterogeneous prescriptions, and patients were not randomly assigned to modality. Detailed patient-level lung DVH data, comprehensive pulmonary toxicity assessments, standardized staging procedures, and central recurrence review were unavailable. Consequently, the favorable reported toxicity cannot be attributed definitively to particle therapy's dosimetric characteristics.
CLINICAL TAKEAWAY
Proton and carbon-ion radiotherapy achieved encouraging long-term disease control with relatively few recorded severe adverse events in a predominantly elderly, medically inoperable population with cT3N0M0 NSCLC. Baseline interstitial lung disease and impaired pulmonary function remained important determinants of outcome and toxicity risk. The findings support particle therapy as a potential definitive option in selected patients, but comparative effectiveness and safety versus modern photon RT remain unproven.